Skip to main content

Table 4 Take-home medications and late clinical outcomes

From: Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study

 

Lower-TG group

Higher-TG group

P

N

157

84

 

Take-home medications

   

  Aspirin (%)

153 (97.5)

84 (100.0)

0.301

  Clopidogrel (%)

154 (98.1)

83 (98.8)

1.000

  *RAAS inhibitor (%)

145 (92.4)

77 (91.7)

1.000

  Beta Blocker (%)

77 (47.2)

47 (56.0)

0.375

  Statin (%)

91 (58)

54 (64.3)

0.414

  Fibrate (%)

2 (1.3)

11 (13.1)

<0.001

Follow-up years (mean)

1.23 (0.22-3.78)

1.40 (0.44-3.73)

0.126

MACE

   

  Non-fatal MI (%)

17 (10.8)

3 (3.6)

0.0731†

  TVR (%)

34 (21.7)

8 (9.5)

0.0111†

  De novo lesion (%)

9 (5.7)

4(4.8)

0.404†

  Cardiac Death (%)

7 (4.5)

0 (0)

0.1688†

  All-Cause Mortality (%)

13 (8.3)

1 (1.2)

0.1392†

  Overall (%)

41 (26.1)

10 (11.9)

0.0137†

  1. *Including angiotensin-converting-enzyme inhibitors and angiotensin-II receptor blockers. †derived from Log-Rank test. MACE, major adverse cardiovascular events; MI, myocardial infarction; RAAS, rennin-angiotensin-aldosterone system; TVR, target vessel revascularization.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us